BioSpace News Archive

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NYSE: CGC) is pleased to announce that effective January 14, 2020, David Klein has been appointed as the Company’s Chief Executive Officer.

LHC Group, Inc. and LifePoint Health announced a further expansion of their joint venture partnership with an agreement to add two additional locations – a home health provider and a hospice provider – in Bryant, Ark., that are associated with LifePoint’s Saline Memorial Hospital.

Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced the presentation of updated clinical data from its ongoing trial evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease

Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a U.S. Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product

The Incheon Metropolitan City government announced an ambitious plan for developing the Songdo Global Biotech Cluster in the Incheon Free Economic Zone.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress made in AgeX’s first year as a public company, as well as current initiatives and future plans.

Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it has completed a $26.4 million private placement of common stock and warrants.

Algiax Pharmaceuticals finalizes financing round and welcomes OCCIDENT and a German family office as new investors on board.

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented data on the cost effectiveness of Doptelet® for the treatment of thrombocytopenia in patients with chronic liver diseases who are scheduled to undergo a procedure at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.